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Abstract 
The prevalence and spectrum of germline mutations in BRCA1 and BRCA2 have been 
reported in single populations, with the majority of reports focused on Caucasians in Europe 
and North America. The Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) has 
assembled data on 18,435 families with BRCA1 mutations and 11,351 families with BRCA2 
mutations ascertained from 69 centers in 49 countries on 6 continents. This study 
comprehensively describes the characteristics of the 1,650 unique BRCA1 and 1,731 unique 
BRCA2 deleterious (disease-associated) mutations identified in the CIMBA database. We 
observed substantial variation in mutation type and frequency by geographical region and 
race/ethnicity. In addition to known founder mutations, mutations of relatively high frequency 
were identified in specific racial/ethnic or geographic groups that may reflect founder 
mutations and which could be used in targeted (panel) first pass genotyping for specific 
populations. Knowledge of the population-specific mutational spectrum in BRCA1 and 
BRCA2 could inform efficient strategies for genetic testing and may justify a more broad-
based oncogenetic testing in some populations. 
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BACKGROUND 
Women who carry germline mutations in either BRCA1 [OMIM 113705] or BRCA2 [600185] 
are at a greatly increased risk of breast and ovarian cancers. Estimates of cancer risk 
associated with BRCA1 and BRCA2 mutations vary depending on the population studied. 
For mutations in BRCA1, the estimated average risk of breast and ovarian cancers ranges 
from 57-65% and 20-50%, respectively (Chen and Parmigiani, 2007; Kuchenbaecker, et al., 
2017). For BRCA2, average risk estimates range from 35-57% and 5-23%, respectively 
(Chen and Parmigiani, 2007; Kuchenbaecker, et al., 2017). Mutation-specific cancer risks 
have been reported that suggest breast cancer cluster regions (BCCR) and ovarian cancer 
cluster regions (OCCR) exist in both BRCA1 and BRCA2 (Kuchenbaecker, et al., 2017; 
Rebbeck, et al., 2015). The identification of mutations in BRCA1 or BRCA2 has important 
clinical implications, as knowledge of their presence is important for risk assessment and 
informs medical management for patients. Interventions, such as risk-reducing bilateral 
mastectomy and salpingo-oophorectomy or annual breast MRI screening, are available to 
women who carry deleterious BRCA1 or BRCA2 mutations to enable early detection of 
breast cancer and for active risk reduction by risk-reducing surgery (Domchek, et al., 2010; 
Rebbeck, et al., 2002; Saslow, et al., 2007). The presence of BRCA1 or BRCA2 mutations 
also can influence cancer treatment decisions, principally around the use of platinum agents 
or poly (ADP-ribose) polymerase (PARP) inhibitors (Lord and Ashworth, 2017) or 
contralateral risk-reducing mastectomy. Increasing numbers of women are having clinical 
genetic testing for BRCA1 and BRCA2 mutations, and recommendations continue to expand 
to whom testing should be offered (NCCN, 2017).  
 
In whites drawn from the general populations in North America and the United Kingdom, the 
prevalence of BRCA1 and BRCA2 mutations has been estimated around a broad range from 
0.1-0.3%, and 0.1-0.7%, respectively (Peto, et al., 1999; Struewing, et al., 1997; Whittemore, 
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et al., 2004).  The Australian Lifepool study, studying a control population consisting of 
cancer-free women ascertained via population-based mammographic screening program, 
estimated the overall frequency of BRCA1 and BRCA2 mutations to be 0.65% (1:153), with 
BRCA1 mutations at 0.20% (1:500) and BRCA2 mutations at 0.45% (1:222) (Thompson, et 
al., 2016).  Estimates from the Exome Aggregation Consortium (ExAC) are similar, with 
frequencies of BRCA1 and BRCA2 mutations (excluding The Cancer Genome Atlas (TCGA) 
data) at 0.21% (1:480) and 0.31% (1:327), respectively; or combined at 0.51% (1:195) 
(Maxwell, et al., 2016).  As they do not include large genomic rearrangements, some newer 
population-based estimates may still under-represent the total number of BRCA1 and 
BRCA2 mutations.  Although the overall prevalence of BRCA1 and BRCA2 mutations in 
most general populations is low, many hundreds of thousands of yet-to-be-tested individuals 
worldwide carry these mutations.  
The prevalence of founder mutations in some racial/ethnic groups is much higher. For 
example, the mutations BRCA1 c.5266dup (5382insC), BRCA1 c.68_69del (185delAG) and 
BRCA2 c.5946del (6174delT), have a combined prevalence of 2-3% in U.S. Ashkenazi Jews 
(Roa, et al., 1996; Struewing, et al., 1997; Whittemore, et al., 2004). For these mutations, 
double heterozygotes in BRCA1 and BRCA2 also have been reported (Friedman, et al., 
1998; Moslehi, et al., 2000; Ramus, et al., 1997a; Rebbeck, et al., 2016). Several other 
founder mutations have been identified, including the Icelandic founder mutation BRCA2 
c.771_775del (999del5) (Thorlacius, et al., 1996); the French Canadian mutations BRCA1 
c.4327C>T (C4446T), and BRCA2 c.8537_8538del (8765delAG) (Oros, et al., 2006b; Tonin, 
et al., 1999; Tonin, et al., 2001); the BRCA1 mutations c.181T>G, and c.4034delA in 
Central-Eastern Europe (Gorski, et al., 2000); the BRCA1 c.548-4185del in Mexico 
(Villarreal-Garza, et al., 2015b; Weitzel, et al., 2013)(Villarreal-Garza, et al., 2015b; Weitzel, 
et al., 2013), the BRCA2 mutation c.9097dup in Hungary (Ramus, et al., 1997b; Van Der 
Looij, et al., 2000) and others. These mutations represent the majority of mutations observed 
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in these populations and have been confirmed as true founder mutations as they have 
common ancestral haplotypes (Neuhausen, et al., 1996, 1998; Oros, et al., 2006a). 
Recurrent mutations have been identified in other populations, but they represent a smaller 
proportion of all unique BRCA1 and BRCA2 mutations, and have not been characterized as 
true founder mutations. There are multiple recurrent mutations in Scandinavian, Dutch, 
French, and Italian populations (Ferla, et al., 2007). Similarly, a number of recurrent 
mutations specific to non-European populations also have been reported in 
Hispanic/Mexican, African-American, Middle Eastern, and Asian populations (Bu, et al., 
2016; Ferla, et al., 2007; Kurian, 2010; Lang, et al., 2017; Ossa and Torres, 2016; Villarreal-
Garza, et al., 2015b).  
The mutational spectra in BRCA1 and BRCA2 are best delineated in whites from Europe 
and North America. However, data on mutational spectra in non-white populations of Asian, 
African, Mediterranean, South-American and Mexican Hispanic descent have also been 
reported (Abugattas, et al., 2015; Ahn, et al., 2007; Alemar, et al., 2016; Bu, et al., 2016; 
Eachkoti, et al., 2007; Ferla, et al., 2007; Gao, et al., 2000; Gonzalez-Hormazabal, et al.; Ho, 
et al., 2000; Jara, et al., 2006; John, et al., 2007; Kurian, 2010; Laitman, et al.; Lang, et al., 
2017; Lee, et al., 2003; Li, et al., 2006; Nanda, et al., 2005; Ossa and Torres, 2016; Pal, et 
al., 2004; Rodríguez, et al., 2012; Seong, et al., 2009; Sharifah, et al.; Solano, et al., 2017; 
Song, et al., 2005; Song, et al., 2006; Toh, et al., 2008; Torres, et al., 2007; Troudi, et al., 
2007; Villarreal-Garza, et al., 2015b; Vogel, et al., 2007; Weitzel, et al., 2005; Weitzel, et al., 
2007; Zhang, et al., 2009). In the current study, we provide a global description of BRCA1 
and BRCA2 mutations by geography and race/ethnicity from the investigators of the 
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). 
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METHODS 
Details of centers participating in CIMBA and data collection protocols have been reported 
previously (Antoniou, et al., 2007).  Details of the CIMBA initiative and information about the 
participating centers can be found at http://cimba.ccge.medschl.cam.ac.uk/h (Chenevix-
Trench, et al., 2007).  All included mutation carriers participated in clinical or research 
studies at the host institutions after providing informed consent under IRB-approved 
protocols. Sixty-nine centers and multicenter consortia submitted data that met the CIMBA 
inclusion criteria (Antoniou, et al., 2007). Only female carriers with pathogenic BRCA1 and/or 
BRCA2 mutations were included in the current analysis. One mutation carrier per family in 
the CIMBA database was included in this report. The actual family relationships (e.g., 
pedigrees) were not available, but a variable that defined family membership supplied by 
each center was used for this purpose. Less than 1% of families (86 of 29,700) had two 
family members with two different mutations.  In these situations, each mutation observed in 
the family was included in the analysis.  In the case of the 94 dual mutation carriers (i.e., 
individuals with both BRCA1 and BRCA2 mutations), one of the two mutations was chosen 
at random for inclusion in the analysis.  
 
The CIMBA data set was used to describe the distribution of mutations by effect and 
function. For the remaining analyses, mutations were excluded if self-reported race/ethnicity 
data were missing. Pathogenicity of mutation was defined as follows: 1) generating a 
premature termination codon (PTC), except variants generating a PTC after codon 1854 in 
BRCA1 and after codon 3309 of BRCA2; 2) large in-frame deletions that span one or more 
exons; and 3) deletion of transcription regulatory regions (promoter and/or first exon) 
expected to cause lack of expression of mutant allele. We also included missense variants 
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considered pathogenic by using multifactorial likelihood approaches (Bernstein, et al., 2006; 
Goldgar, et al., 2004). Mutations that did not meet the above criteria but have been classified 
as pathogenic by Myriad Genetics, Inc. (Salt Lake City, UT) also were included. 
Classification of nonsense-mediated decay (NMD) was based on in-silico predictions and 
was not based on molecular classification (Anczukow, et al., 2008).  
 
Contingency table analysis using a chi-square test was used to test for differences in 
dichotomous variables, as was a t-test for continuous variables. Mutation counts are 
presented as the number of families with the mutation. Fisher’s exact tests were used if 
sample sizes in any contingency table cell were less than five. Analyses were done in 
STATA, v. 14.2.  
 
RESULTS  
Mutations in BRCA1 and BRCA2 
From the 26,861 BRCA1 and 16,954 BRCA2 mutation carriers in the CIMBA data set as of 
June 2017, 18,435 families with BRCA1 mutations and 11,351 families with BRCA2 
mutations were studied to count only one occurrence of a mutation per family. Figure 1 
shows the countries that contributed mutations to this report. From among these families, 
1,650 unique BRCA1 and 1,731 unique BRCA2 mutations were identified. The unique 
mutations and number of families in which each mutation was observed are listed in 
Supplementary Table 1. In each gene, the five most common mutations (including founder 
mutations) accounted for 33% of all mutations in BRCA1 (8,739 of 26,861 mutation carriers) 
and 19% of all mutations in BRCA2 (3,244 of 16,954 mutation carriers). A web site 
containing information about the most common mutations reported here can be found at: 
http://apps.ccge.medschl.cam.ac.uk/consortia/cimba/.  This information may be periodically 
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updated as new data become available. 
 
Mutation Type and Effect  
Table 1 presents a summary of the type of BRCA1 or BRCA2 mutations and their predicted 
effect on transcription and translation. The most common mutation type was frameshift 
followed by nonsense. The most common effect of BRCA1 and BRCA2 mutations was 
premature translation termination and most of the mutant mRNAs were predicted to undergo 
nonsense-mediated mRNA decay (NMD) (Anczukow, et al., 2008). Despite having the same 
spectrum of mutations in BRCA1 and BRCA2, the frequency distribution by mutation type, 
effect, or function differed significantly (p<0.05) between BRCA1 and BRCA2 mutation 
carriers for many groups, as shown in Table 1. These observed differences are largely 
because genomic rearrangements and missense mutations account for a much higher 
proportion of mutations in BRCA1 when compared with BRCA2, as previously described 
(Welcsh and King, 2001). 
 
We and others have found that breast (BCCR) and ovarian (OCCR) cancer cluster regions 
exist that may confer differential cancer risks (Gayther, et al., 1997; Gayther, et al., 1995; 
Kuchenbaecker, et al., 2017; Rebbeck, et al., 2015). Figure 2 reports the relative frequency 
of mutations in the BCCR and OCCR by race/ethnicity. Compared with whites, we observed 
differences in the relative frequency of mutations in the BRCA1 BCCR and OCCR in Asians 
and Hispanics, and in the BRCA2 OCCR in Hispanics.  To the degree that the mutations 
within the BCCRs and OCCRs conferred differential cancer risks, these data suggest that 
BRCA1 and BRCA2 mutation-associated cancer risks may vary by race/ethnicity. 
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Geography and Race/Ethnicity 
The most common mutations by country are summarized in Table 2 (BRCA1) and Table 3 
(BRCA2). The locations of the mutations that were observed in African American, Asian, and 
Hispanic populations are depicted in Figure 3 (BRCA1) and Figure 4 (BRCA2). Some 
countries (Albania, Bosnia, Costa Rica, Ireland, Honduras, Japan, Norway, Peru, 
Philippines, Qatar, Saudi Arabia, Romania, Venezuela and Turkey) contributed fewer than 
10 mutation carriers to the CIMBA database. Many of these mutations were submitted to the 
central database by CIMBA centers that ascertained these patients, but these patients 
originated from a different country. Based on such small numbers, it was impossible to make 
inferences about the relative importance of mutations in these locations.  A description of the 
major ethnicity by country is provided in Supplementary Table 2. 
 
The mutational distribution among the major racial/ethnic groups and by geography are 
summarized in Tables 4 and 5. Table 4 includes only those individuals for whom self-
identified race/ethnicity was recorded. Note that in some countries it is prohibited to collect 
data on race and ethnicity, so this information is missing.  Among the 10 most common 
BRCA1 mutations in each racial/ethnic group, a few were seen in several populations, 
including the recurrent Jewish and Eastern European founder mutations c.5266dup 
(5382insC) and c.68_69del (185delAG); c.815_824dup in African-Americans and Hispanics; 
c.3756_3759del in Caucasian and Jews; and c.5503C>T and c.3770_3771del in Asians and 
Jews. Similarly, recurrent mutations in BRCA2 included c.5946del (6174delT) in whites and 
Jews; c.2808_2811del in whites, African Americans, Asians, Hispanics, and Jews; 
c.6275_6276del in whites and Hispanics; c.3847_3848del in whites and Jews; c.658_659del 
in African Americans and Hispanics; and c.3264dup in Hispanics and Jews. The majority of 
other recurrent BRCA1 and BRCA2 mutations were only observed within a single 
racial/ethnic group, particularly African Americans, Asians, and Hispanics. Of note, the vast 
  
 
This article is protected by copyright. All rights reserved. 
 
21 
majority of women who self-identified as Jewish carry the Ashkenazi Jewish founder 
mutations BRCA1 c.5266dup and c.68_69del and BRCA2 c.5946del. Only 72 (3.9%) of 
1,852 BRCA1 mutation carrier families and 55 (5.6%) of 990 BRCA2 mutation carrier 
families who self-identified as being Jewish carried other (non-founder) mutations. However, 
since many individuals of self-identified Jewish ancestry are only tested for the three founder 
mutations, this number is likely to be underestimated. 
 
In African Americans, the majority of BRCA1 mutations were not observed in any other 
racial/ethnic group, implying these mutations may be of African origin. In Hispanics, the most 
common BRCA1 mutations also were observed among individuals from other regions who 
did not self-identify as Hispanic, including BRCA1 c.3331_3334del (also observed in 
Australia, Europe, USA, and the UK), and BRCA1 c.68_69del (the Jewish founder mutation) 
(Weitzel, et al., 2013; Weitzel, et al., 2005).  The BRCA1 c.815_824dup mutation has been 
reported as being of African origin, but has also been reported as a recurrent mutation in 
Mexican-Americans, perhaps as a reflection of the complex continental admixture of this 
population (Villarreal-Garza, et al., 2015b). BRCA1 c.390C>A and c.5496_5506delinsA were 
most commonly found in the Asian population. In BRCA2, c.2808_2811del was found among 
the 10 most frequent mutations in all races/ethnicities. 
 
Recurrent Mutations 
As expected, the most common mutations in the entire data set were the founder mutations 
BRCA1 c.5266dup (5382insC), BRCA1 c.68_69del (185delAG), and BRCA2 c.5946del 
(6174delT). In part, the high frequency of these mutations is a consequence of panels that 
facilitate testing for these three mutations in women of Jewish descent. However, these two 
BRCA1 mutations also are relatively common in regions with a low proportion of individuals 
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who self-identify as Jewish (e.g., Hungary, Czech Republic, France, Germany, Italy, Poland 
Spain, Russia, and UK). BRCA1 c.5266dup is a founder mutation thought to have originated 
1800 years ago in Scandinavia/Northern Russia, entering the Ashkenazi-Jewish population 
400-500 years ago, and thus has origins and a spread pattern independent of the 
Ashkenazim (Hamel, et al., 2011). Haplotype studies have been used to determine the origin 
of BRCA1 c.68_69delAG in populations not considered to have a high proportion of Jewish 
ancestry. In some populations, such as the Hispanics in the USA and Latin American, it is 
associated with the Ashkenazi Jewish haplotype, presumably due to unrecognized (Jewish) 
ancestry (Ah Mew, et al., 2002; Velez, et al., 2012; Weitzel, et al., 2005). In other 
populations, such as Pakistani and Malaysians, where BRCA1 c.68_69del is a recurrent 
mutation, it appears to have arisen independently, as it is carried on a distinct haplotype 
(Kadalmani, et al., 2007; Rashid, et al., 2006). A different haplotype was also reported for 
several British families (the ‘Yorkshire haplotype’) that is distinct from both the Jewish and 
the Indian-Pakistani haplotypes (Laitman, et al., 2013; Neuhausen, et al., 1996).  
 
The only locations in which these three founder mutations were not commonly observed 
were Belgium and Iceland. Iceland has another founder mutation (i.e., BRCA2 
c.771_775del).  Yet other founder mutations included BRCA1 c.4327C>T and BRCA2 
c.8537_8538del in Quebec. This latter mutation in BRCA2 also is the most common 
mutation in high-risk families in Sardinia (Pisano, et al., 2000) and was also reported in a few 
Jewish Yemenite families, with a distinct haplotype(Palomba, et al., 2007). The BRCA1 
c.181T>G mutation was observed in Central Europe (Austria, Czech Republic, Germany, 
Hungary, Italy and Poland), but also observed in the US, Argentina, Latvia, Lithuania and 
Israel. This mutation has been found on a common haplotype in individuals of Polish and 
Ashkenazi Jewish ancestry, suggesting it is an Eastern European founder mutation 
(Kaufman, et al., 2009).  The large rearrangement mutation in BRCA1 c.548-?4185+?del 
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(ex9-12del) appears to be an important founder mutation in Mexico, with findings of a 
common haplotype and an estimated age at 74 generations (~1,500 years) (Weitzel, et al., 
2013). 
 
We observed a number of other recurrent mutations. BRCA1 c.3331_3334del comprised 
more than half of all mutations identified in Colombia, consistent with a previous report that 
this is a founder mutation in the Colombian population (Torres, et al., 2007). However, this 
mutation has not been found at high rates in a second Colombian population (Cock-Rada, et 
al., 2017). BRCA2 c.2808_2811del was frequently observed, not only as the most common 
mutation in France and Colombia, but also in other Western and Southern European 
countries, and destinations to which individuals from these countries have migrated. It 
estimated to have arisen approximately 80 (46-134) generations ago. However, due to the 
diversity of the haplotypes, multiple independent origins could not be ruled out (Neuhausen, 
et al., 1998). BRCA2 c.6275_6276del was a recurrent BRCA2 mutation in Australia, the UK, 
Belgium, Spain, the Netherlands, and North America. This mutation has been estimated to 
have originated 52 (24-98) generations ago from a single founder (Neuhausen, et al., 1998). 
Recurrent or founder mutations were observed in diverse populations. For example, the 
c.115T>G (Cys39Gly) mutation has been described in Greenlanders (Hansen, et al., 2009).  
The c.2641G >T and c.7934del mutations have both been reported as founder mutation in 
South African Afrikaners (Reeves, et al., 2004).  
 
DISCUSSION  
We have reported worldwide distribution of BRCA1 and BRCA2 mutations curated in the 
CIMBA dataset. These results may aid in the understanding of the mutation distribution in 
specific populations as well as imparting clinical and biological implications for our 
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understanding of BRCA1- and BRCA2-associated carcinogenesis.  
 
Clinical testing for BRCA1 and BRCA2 mutations has benefited substantially from 
knowledge about common mutations in specific populations. In many countries, the three 
Ashkenazi-Jewish founder mutations are offered as a mutation testing panel for self-reported 
Ashkenazim, based on their frequency. This approach is much less expensive than 
comprehensive gene sequencing. The identification of commonly-occurring mutations in 
other populations could lead to more efficient and cost-effective mutation testing for BRCA1 
and BRCA2.  For example, Villareal-Garza et al. (Villarreal-Garza, et al., 2015a) have 
developed the HISPANEL of mutations that optimizes testing in Hispanic/Latino populations. 
In the present study, we have identified mutations that may exist at a sufficient prevalence to 
warrant consideration for population-specific mutation testing panels. Criteria for developing 
such panels for BRCA1 and BRCA2 mutation screening are not available. However, 
mutations that are in a specific population and that capture a sufficient percentage of 
mutations in high risk individuals and families in that population may be appropriate for use 
in targeted genetic testing. Before such panels can be developed, population-based studies 
of mutation frequency in specific populations should be undertaken. The data reported 
herein provide a list of the recurrent mutations around which such panels could be 
developed, but the frequencies are not population-based, particularly in settings where 
founder mutations are preferentially screened (e.g., the Jewish founder panels). Similarly, 
putative founder mutations identified by assessing common ancestral origins of specific 
mutations (rather than just high prevalence; Table 5) may form the basis of population-
specific BRCA1 and BRCA2 mutation screening panels. 
 
We report the distribution of BRCA1 and BRCA2 mutations in nearly 30,000 families of 
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bona-fide disease-associated mutations. The strengths of this report include the large 
sample size that reflects a geographically and racially/ethnically diverse set of BRCA1 and 
BRCA2 mutation carriers. However, some limitations need to be considered. First, the 
sample set presented here does not reflect a systematic study of these populations or 
races/ethnicities; the data reflect patterns of recruitment (e.g., individuals with higher risk or 
prior diagnosis of cancer who consented to participate in research protocols) that contributed 
to the CIMBA consortium. Certain racial/ethnic or socio-demographic groups are under- or 
over-represented or missing in our data set and, as a consequence, mutations may be over- 
or under-represented. For example, the existence of a commercial panel of three Jewish 
founder mutations enhances genetic testing for those mutations. As a result, the most 
frequently observed mutations in some populations (e.g., the USA) reflect the widespread 
use of this testing panel in the USA population. Similar arguments may also apply for other 
populations, where testing for certain founder mutations may be more frequent.  Therefore 
the relative frequencies of mutations by population in the present study may be subject to 
such testing biases. Comparing the relative frequencies is also complicated by the inclusion 
of related individuals.   
 
Second, although the CIMBA data represent most regions around the world, there are 
limitations related to which groups of individuals have been tested and which centers 
contributed data. In particular, non-white ancestry populations are still under-represented in 
research reports of mutation spectrum and frequency. Genetic testing in the developing 
world remains limited.  
 
Third, we presented the mutations in terms of type or effect (Table 1), but these 
designations are not always based on experimental evidence. For example, NMD mutation 
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status is almost always defined by a prediction rule rather than in vitro experiments that 
confirm the presence of nonsense mediated decay.  
 
Fourth, we presented the occurrence of putative founder mutations. Some of these founder 
mutations (e.g., BRCA1 c.68_69del, BRCA2 c.771_775del) have been demonstrated to be 
true founder mutations based on actual ancestry analyses. Others, however, have only been 
identified as occurring commonly in certain populations, but haplotype or similar analyses of 
founder status may not have been done.  
 
Fifth, our analysis was based on self-reported race/ethnicity of study participants, but this 
information may misclassify some groups of individuals. For example, some Middle Eastern 
groups may have been classified as “Caucasian” based on the data available, but in fact 
may represent a distinct group that was not captured here. Moreover, in some large centers 
participating in CIMBA, collecting information on race/ethnicity is prohibited and these 
mutation carriers were excluded from the comparisons.  
 
Finally, we evaluated mutations by racial/ethnic and geographic designations, but some of 
these may be misclassified. For example, while BRCA1 c.68_69del has been shown to arise 
independently of the Jewish founder mutation in Pakistan (Rashid, et al., 2006), we cannot 
determine if the identified group also contains some Ashkenazi Jewish individuals. 
 
The data presented herein provide new insights into the worldwide distribution of BRCA1 
and BRCA2 mutations. The identification of recurrent mutations in some racial/ethnic groups 
or geographical locations raises the possibility of defining more efficient strategies for 
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genetic testing. Three Jewish founder mutations BRCA1 c.5266dup (5382insC) and BRCA1 
c.68_69del (185delAG) and BRCA2 c.5946del (6174delT) have long been used as a primary 
genetic screening test for women of Jewish descent. The identification here of other 
recurrent mutations in specific populations may similarly provide the basis for other mutation-
specific panels. For example, BRCA1 c.5266dup (5382insC) may be a useful as a single 
mutation screening test in Central-Eastern European populations before undertaking full 
sequencing. However, this basic test may be supplemented with screening for BRCA1 
c.181T>G, as the second most common mutation of the region, and for some special cases, 
to include most common Hungarian BRCA2 founder mutation c.9097dup (9326insA) for 
those with Hungarian ancestry (van der Looij, et al., 2000, Ramus, et al., 1997b). In Iceland, 
only two mutations were reported: the founder mutation BRCA2 c.771_775del and the rarer 
BRCA1 c.5074G>A (Bergthorsson, et al., 1998). A number of other situations can be 
identified in which specific mutations explain a large proportion of the total mutations 
observed in a population. These and other such examples suggest that targeted mutation 
testing panels which include specific mutations could be developed for use in specific 
populations. Finally, we focused on female BRCA1 and BRCA2 mutation carriers in this 
report. However, the growing knowledge about BRCA1 and BRCA2-associated cancers in 
men, particularly prostate cancer (Ostrander and Udler, 2008; Pritchard, et al., 2016), 
suggests that the information presented herein will also have value in genetic testing of men. 
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Figure 1. Countries (in red) that provided data on BRCA1 and/or BRCA2 mutation carriers in this report. 
Race/ethnic breakdown is reported for countries with more than 100 observations with multiple 
ethnicities totaling at least 10% of the country’s sample (i.e., Australia, Brazil, Canada, USA). 
 
 
Figure 2. Proportion of Mutations in the Breast Cancer Cluster Regions (BCCR) and Ovarian Cancer 
Cluster Region (OCCR) in BRCA1 and BRCA2 by Ethnicity as defined previously(Rebbeck, et al., 2015). 
Asterisk indicates proportion is significantly different than Caucasian proportion (p-value<0.05). 
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Figure 3: BRCA1 Mutation Distribution in African American, Asian, and Hispanic. Length of mutation 
indicator reflects the number of observed mutations. Domains are Zinc/Ring finger (green); BRCT 
domain (red); BRCT (C terminus) (blue). Mutation type is indicated for each mutation by color: green: 
missense mutations; black: truncating mutations (nonsense, nonstop, frameshift deletion, frameshift 
insertion, splice site, in-frame mutations); purple: all other types of mutations. 
 
Figure 4: BRCA2 Mutation Distribution in African American, Asian, and Hispanic CIMBA Sample (per 
family). Length of mutation indicator reflects the number of observed mutations. Domains are BRCA 
repeats (green); BRCA helica (red); OB binding domain (blue); tower (yellow) and OB3 binding domain 
(purple). Mutation type is indicated for each mutation by color: green: missense mutations; black: 
truncating mutations (nonsense, nonstop, frameshift deletion, frameshift insertion, splice site, in-frame 
mutations); purple: all other types of mutations. 
 
Table 1: Characteristics of BRCA1 and BRCA2 Mutations in the CIMBA Database (by 
unique mutation) 
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   BRCA1 (N=1,650) BRCA2 (N=1,731) p-value 
 Designation Definition N % N %  
Mutation Type Large Deletion (DL) Genomic DNA deletion  (encompassing at 
least 1 exon) 
130 7.9 34 1.9 <0.0001 
 Large Duplication (DP) Genomic DNA duplication  (encompassing at 
least 1 exon) 
27 1.6 11 0.6 0.010 
 Frameshift (FS) Deletion or insertion resulting in a 
disruption of the open reading frame 
948 57.5 1,141 65.9 <0.0001 
 In-Frame Deletion (IFD) Small deletions, splice site mutations or large 
genomic rearrangements that result in a 
change in the mRNA but do not change the 
open reading frame 
1 <0.1 2 0.1 0.518 
 Missense (MS) Results in an altered amino acid 46 2.8 13 0.8 0.0001 
 Nonsense (NS) Point mutation resulting in a stop codon 313 19.0 380 22.0 0.027 
 Splice (SP) Results in aberrant RNA splicing 166 10.1 131 7.6 0.013 
 Multiple Types 
(including those listed 
above) 
 20 1.1 19 1.1 1.00 
Mutation 
Effect 
No RNA Mutation is predicted to abrogate RNA 
production 
21 1.3 6 0.3 0.003 
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 Premature Termination 
Codon (PTC) 
Result of a nonsense substitution, frameshift 
due to small deletion or insertion, aberrant 
splicing, or large genomic rearrangement 
1,331 81.0 1,542 89.0 <0.0001 
 Unknown/Other Unknown effect 298 18.0 183 10.6 <0.0001 
Mutation 
Function 
Nonsense-Mediated 
Decay (NMD)* 
(Anczukow, et al., 2008) 
Mutation is predicted to result in reduced 
transcript level due to decay of RNA and/or 
degradation/instability of truncated proteins 
1,213 73.9 1,523 88.0 <0.0001 
 No NMD Mutations generating a premature stop 
codon in the first or last exon that is 
predicted not to result in NMD 
58 3.5 16 0.9 <0.0001 
 No RNA Loss of expression due to deletion of 
promoter and/or transcription start site 
21 1.3 6 0.4 0.003 
 Re-Initiation Mutations presumed to result in translation 
re-initiation but produce unstable protein 
4 0.2 0 0.0 0.294 
 NMD/Re-initiation Mutations presumed to result in translation 
re-initiation but produce unstable protein 
60 3.7 0 0.0 -- 
 Unknown/Other Unknown function 294 17.8 187 10.7 <0.0001 
Mutation Class 1 Mutations predicted to be associated with 
unstable or no protein 
1,298 78.6 1,529 88.3 <0.0001 
 2 Mutations predicted to be associated with 
stable mutant proteins 
112 6.8 36 2.1 <0.0001 
 3 Unknown function 240 14.6 167 9.6 <0.0001 
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P-values reflect the comparison of frequencies between BRCA1 and BRCA2 mutation 
carriers. 
*References (Anczukow, et al., 2008; Buisson, et al., 2006; Mikaelsdottir, et al., 2004; 
Perrin-Vidoz, et al., 2002; Ware, et al., 2006) 
 
 
Table 2: Common BRCA1 Mutations by Country of Origin (by family) 
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    Five Most Common Mutations (Number 
Observed) 
Conti-nent Country Families Unique 
Mutations 
1 2 3 4 5 
Africa Nigeria 20 15 c.303T>G(4) c.191G>A(2) c.3268C>T(2) c.4240dup(1) c.4122_4123de
l(1) 
 South 
Africa 
49 16 c.2641G>T(18) c.5266dup(7) c.1374del(4) c.68_69del(4) c.3228_3229de
l(4) 
Asia Hong Kong 70 45 c.470_471del(7) c.4372C>T(5) c.2635G>T(4
) 
c.5406+1_5406
+3del(4) 
c.3342_3345de
l(4) 
 Israel 679 7 c.68_69del(510) c.5266dup(151) c.2934T>G(1
3) 
c.181T>G(2) c.981_982del(1
) 
 Korea 158 61 c.390C>A(19) c.5496_5506delins
A(17) 
c.922_924del
insT(11) 
c.5030_5033de
l(9) 
c.3627dup(8) 
 Malaysia 72 47 c.2635G>T(5) c.68_69del (4) c.470_471del
(3) 
c.4148C>G(3) c.3770_3771de
l(3) 
 Pakistan 93 45 c.5503C>T(11) c. 
3770_3771del(8) 
c.4508C>A(8
) 
c.66dup(6) c.2269del(1) 
 Singapore 28 18 c.2726dup(9) c.2617dup(2) c.2635G>T(2
) 
c.213-
12A>G(1) 
c.3214del(1) 
 Turkey 1 1 c.3333del(1)     
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Australia Australia 581 173 c.68_69del(56)  c.5266dup(45) c.4065_4068
del (23) 
 
c.3756_3759de
l (22) 
c.5503C>T(16) 
Europe Albania 1 1 c.4225C>T (1)     
Europe Austria 391 115 c.181T>G(51) c.5266dup(46) c.3018_3021
del(35) 
c.1687C>T(26) c.962G>A(17) 
 Belgium 166 41 c.2359dup(40) c.212+3A>G(26) c.3661G>T(1
2)  
 c.3607C>T(10) c.3841C>T(9) 
 Bosnia 1 1 c.4158_4162del(1)     
 Czech Rep. 208 42 c.5266dup(87) c.3700_3704del(25
) 
c.181T>G(20
) 
c.1687C>T(16) c.3756_3759de
l(6) 
 Denmark 667 101 c.2475del(91) c.3319G>T(81) c.5266dup(4
1) 
c.3710del(39) c.c.5213G>A(3
0) 
 Finland 57 31 c.3485del(8) c. .4097-2A>G (5) c 5266dup(4) c.1687C>T42) c.4327C>T(3) 
 France 1,522 418 c.5266dup(118) c.3481_3491del(70
) 
c.68_69del(6
3) 
c.4327C>T(49) c.3839_3843de
linsAGGC (40) 
 Germany 2,287 381 c.5266dup(411) c.181T>G(196) c.4689C>G(6
3) 
c.1687C>T(62) c.3481_3491de
l(55) 
 Greece 208 41 c.5266dup(47) c.5212G>A(29) c.5406+644_*
8273del(24) 
c.5468-
285_5592+ 
4019delinsCAC
AG(23) 
c.5251C>T(13) 
 Hungary 235 47 c.5266dup(78) c.181T>G(60) c.68_69del(2
2) 
c.5278-
?_5406+?del(5) 
c.5251C>T(4) 
 Iceland 3 1 c.5074G>A(3)     
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 Ireland 2 2 c.547+1G>T(1) c.427G>T(1)      
 Italy 1,120 254 c.5266dup(124) c.181T>G(44) c.190T>C(43) c.1687C>T(39) c.1380dup(37) 
 Latvia 100 9 c.5266dup(49) c.4035del(40) c.181T>G(5) c.3756_3759de
l(1) 
c.4675G>A(1) 
 Lithuania 223 21 c.4035del(112) c.5266dup(58) c.181T>G221
) 
c.1687C>T(5) c5177_5180del
(4) 
 Netherland
s 
782 126 c.5333-36_5406+ 400del(87) c.5277+1G>A(66) c.2685_2686
del(60) 
c.2197_2201de
l(41) 
c.5266dup(40) 
 Poland 1,064 8 c.5266dup(711) c.181T>G(276) c.4035del(69
) 
c.5333-
36_5406+400d
el(3) 
.68_69del(2) 
 Portugal 49 23 c.3331_3334del(15) c.2037delinsCC(7) c.3817C>T(3) c.21A>G(2) c.5266dup(2) 
 Romania 1 1 c.5266dup(1)     
 Russia 160 10 c.5266dup(135) c.4035del(11) c.68_69del(7) c.5026_5027de
l(1) 
c.4185+2T>C(1
) 
 Spain 678 181 c.211A>G(78) c.68_69del(62) c.5123C>A(6
1) 
c.3770_3771de
l(23) 
c.3331_3334de
l(23) 
 Sweden 438 108 c.3048_3052dup(68) c.1687C>T(31) c.2475del(27
) 
c.1082_1092de
l(26) 
c.5266dup(19) 
 UK 1,389 297 c.68_69del(134) c.4065_4068del(10
4) 
c.4186-
?_4357+?dup 
(78) 
c.3756_3759de
l(62) 
c.5266dup(60) 
North 
America 
Canada 450 112 c.68_69del(99) c.4327C>T(66) c.5266dup(
50) 
c.2834_2836d
elinsC(16) 
c.3756_3759d
el(12) 
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 USA 4,219 613 c.68_69del(1130) c.5266dup(554) c.181T>G(1
13) 
c.4065_4068d
el(58) 
c.3756_3759(
49) 
 Argentina 89 35 c.68_69del(22) c.5266dup(12) c.211A>G(1
1) 
c.181T>G(6) c.427G>T(3) 
South/ 
Central 
America 
Brazil 101 39 c.5266dup(31) c.3331_3334del(
18) 
c.135-
?_441+?del(
4) 
c.1687C>T(4) c.3916_3917d
el(3) 
 Colombia 55 2 c.3331_3334del(36) c.5123C>A(19)    
 Mexico 25 15 c.548-?4185+?del(8)  c.68_69del(2) c.824_825in
s10(2) 
c.211A>G(2) c.5030_5033d
el(1) 
 Peru 1 1 c.4986+6T>C(1)     
 Venezuela 1 1 c.5123C>A(1)     
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Table 3: Frequently Observed BRCA2 Mutations by Country of Origin (by Family) 
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    Five Most Frequently Observed Mutations (Number Observed) 
Conti-nent Country Families Unique 
Mutations 
1 2 3 4 5 
 Nigeria 12 9 c.1310_1313del(3) c.8817_8820delA(2) c.5241_5242insT
A(1) 
c.2402_2412del(
1) 
c.994del(1) 
Africa South Africa 103 18 c.7934del(80) c.5946del(6) c.6944_6947del(
2) 
c.5213_5216del(
1) 
c.6939del(1) 
Asia Hong Kong 91 45 c.3109C>T(22) c.2808_2811del(5) c.7878G>A(5) c.7007G>T(4) c.9294C>G(4) 
 Israel 339 5 c.5946del(330) c.8537_8538del(5) c.4936_4939del(
2) 
c.3847_3848del(
1) 
c.6024dup(1) 
 Japan 1 1 c.5645C>A(1)     
 Korea 220 93 c.7480C>T(40) c.3744_3747del(18) c.1399A>T(16) c.5576_5579del(
14) 
c.6724_6725del(6) 
 Malaysia 64 47 c.262_263del(8) c.2808_2811del(3) c.3109C>T(3) c.5073dup(3) c.809C>G(2) 
 Pakistan 19 17 c.5222_5225del(3) c.8754+1G>T(1) c.92G>A(1) c.6468_6469del(
1) 
c.2990T>G(1) 
 Philippines 1 1 c.2023del(1)     
 Qatar 1 1 c.7977-1G>C(1)     
 Saudi Arabia 1 1 c.473C>A(1)     
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 Singapore 10 10 c.200_1910-877dup(1) c.2808_2811del(1) c.8961_8964del(
1) 
c.8915del(1) c.956dup(1) 
Australia Australia 496 178 c.5946del(53) c.6275_6276del(25) c.7977-1G>C(11) c.5682C>G(10) c.3487_3848del(10
) 
Europe Austria 185 87 c.8364G>A(17) c.8755-1G>A(15) c.3860del(11) c.1813dup(8) c.7846del(6)  
 Belgium 116 39 c.6275_6276del(17) c.516+1G>T(16) c.8904del(14) c.1389_1390del(
9) 
c.3847_3848del(7)  
 Czech Republic. 81 42 c.8537_8538del(12) c.7913_7917del(5) c.5645C>A(4) c.2808_2811del(
4) 
c.9403del(4) 
 Denmark 442 101 c.7617+1G>A(61) c.6373del(44) c.1310_1313del 
(25) 
c.6486_6489del(
25) 
c.3847_3848del(16
) 
 Finland 52 16 c.9118-2A>G(18) c.7480C>T(12) c.771_775del(7) c.8327T>G(2) c.1286T>G(2) 
 France 997 375 c.2808_2811del(34) c.5946del(27) c.9026_9030del(
22) 
c.8364G>A(22) c.5909C>A(19) 
 Germany 1,109 367 c.1813dup(51) c.3847_3848del(34) c.2808_2811del(
29) 
c.5946del(29) c.5682C>G(23) 
 Greece 28 22 c.7976G>A(3) c.5722_5723del(2) c.9097dup(2) c.9501+1G>A(2) c.5722_5723del(2) 
 Hungary 81 39 c.9097dup(17) c.5946del(11) c. 
7913_7917del(4) 
c.6656C>G(3) c.9403del(3)  
 Iceland 89 1 c.771_775del(89)     
 Ireland 2 2 c.8951C>G(1) c.5576_5579del(1)    
 Italy 706 242 c.8878C>T(33) c.6468_6469del(31) c.7180A>T(29) c.5682C>G(25) c.8247_8248delGA
(18) 
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 Lithuania 26 11 c.658_659del(13) c.3847_3848del(4) c.6580dup(1) c.6410del(1) c.7879A>T(1) 
 Netherlands 493 167 c.6275_6276del(38) c.8067T>A(26) c.5946del(25) c.9672dupA(23) c. 5213_5216del 
(21) 
 Norway 2 1 c.771_775del(2)     
 Poland 23 20 c.5946del(3) c.8946del(2) c. 
7913_7917del(1) 
c.9294C>A(1) c.635_636del(1) 
 Portugal 71 22 c.156_157insAlu(39) c.9097dup(5) c.9382C>T(3) c.682-2A>C(2) c.5645G>A(2) 
 Romania 1 1 c.9097dup(1)     
 Russia 3 3 c.3682_3685del(1) c.5410_5411del(1) c.5946del(1)   
 Spain 670 217 c.3264dup(58) c.2808_2811del(56) c.9026_9030del(
52) 
c.6275_6276del(
32) 
c.9018C>A(16) 
 Sweden 123 68 c.4258del(11) c.2830A>T(7) c.1796_1800del(
6) 
c.3847_3848del(
6) 
c.7558C>T5) 
 UK 1,200 308 c.6275_6276del(107) c.5946del(66) c.4478_4481del(
37) 
c.755_758del(36
) 
c.5682C>G(33) 
North America Canada 311 108 c.8537_8538del(48) c.5946del(45) c.2808_2811del(
13) 
c.6275_6276del(
11) 
c.5857G>T(10) 
 USA 3,064 626 c.5946del(742) c.2808_2811del(86) c.1813dup(62)  c.658_659del(50
) 
c.6275_6276del(49
) 
 Argentina 49 21 c.5946del(18) c.2808_2811del(5) c.6037A>T(4) c.9026_9030del(
2) 
c.5645C>G(2) 
 Brazil 47 33 c.2T>G(5) c.2808_2811del(4) c.156_157insAlu(
4) 
c.6405_6409del(
3) 
c.1138del(2) 
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South/ Central 
America 
Colombia 19 4 c.2808_2811del(15) c.5851_5854del (2) c.6275_6276del(
1) 
c.93G>A(1)  
 Costa Rica 1 1 c.9235del(1)     
 Honduras 1 1 c.7558C>T(1)     
 Mexico 6 6 c.3264dup (1) c.6275_6276del (1) c.2224C>T (1) c.5542del (1) c.6502G>T (1) 
 
 
 
  
 
This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process, which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1002/humu.23406. 
 
This article is protected by copyright. All rights reserved. 
 
 
Table 4. Ten Most Frequently Observed Mutations by Self-Identified Race/Ethnicity 
(%) (by Family) 
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 Mutation 
Rank 
Caucasian African American Asian Hispanic/Latino Jewish Other 
BRCA1  1 c.5266dup(17%) c.815_824dup(16%) c.390C>A(4%) c.68_69del(12%) c.68_69del(72%) c.5266dup(12
%) 
 2 c.181T>G (6%) c.5324T>G (7%) c.5496_5506delinsA 
(3%) 
c.3331_3334del(10%) c.5266dup(24%) c.68_69del(17
%) 
 3 c.68_69del(6%) c.5177_5180del(5%) c.470_471del(3%) c.5123C>A(9%) c.3756_3759del 
(0.3%) 
c.181T>G(5%) 
 4 c.4035del(2%) c.4357+1G>A(5%) c.5503C>T(2%) c.548-
?_4185+?del(7%) 
c.1757del(0.3%) c.5333-
36_5406+400d
el(3%) 
 5 c.4065_4068del(2%) c.190T>G(3%) c.922_924delinsT(2%) c.211A>G(5%) c.2934T>G(0.2%) c.3481_3491de
l(2%) 
 6 c.3756_3759del(2%) c.68_69del(3%) c.68_69del(2%) c.815_824del(3%) c.5503C>T(0.1%) c.1687C>T 
(2%) 
 7 c.1687C>T(2%) c.5467+1G>A(3%) c.3770_3771del(2%) c.2433del(3%) c.4185+1G>T(0.1%) c.4065_4068de
l(2%) 
 8 c.4327C>T(2%) c.182G>A(3%) c.2635G>T(2%) c.1960A>T(3%) c.4689C>G(0.1%) c.5277+1G>A 
(2%) 
 9 c.2475del(2%) c.5251C>T(2%) c.2726dup(2%) c.3029_3030del(3%) c.3770_3771del 
(0.1%) 
c.2685_2686de
l(68%) 
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 10 c.4186-
?_4357+?dup(1%) 
c.4484G>T(2%) c.3627dup(2%) c.4327C>T(2%) c.4936del(0.1%) c.4327C>T(1%
) 
Families 11,258 174 550 408 1,852 4,583  
Unique 
Mutations 
1,206 77 240 104 56 765  
BRCA2 1 c.5946del(5%) c.2808_2811del(6%) c.7480C>T(8%) c.3264dup(17%) c.5946del(94%) c.5946del(5%) 
 2 c.6275_6276del(3%) c.4552del(6%) c.3109C>T(6%) c.2808_2811del(9%) c.3847_3848del 
(0.4%) 
c.6275_6276de
l(4%) 
 3 c.2808_2811del(3%) c.9382C>T(5%) c.3744_3747del(4%) c.145G>T(5%) c.1754del(0.4%) c.2808_2811de
l(3%) 
 4 c.771_775del(2%) c.1310_1313del(4%) c.1399A>T(3%) c.9026_9030del(3%) c.9382C>T(0.3%) c.1813dup(3%
) 
 5 c.3847_3848del(2%) c.5616_5620del(4%) c.5576_5579del(3%) c.658_659del(3%) c.5621_5624del 
(0.2%) 
c.5645C>A(2%
) 
 6 c.5682C>G(2%)  c.6405_6409del(3%) c.2808_2811del(2%) c.5542del(3%) c.2808_2811del 
(0.2%) 
c.1310_1313de
l(2%) 
 7 c.1813dup(2%) c.658_659del(3%) c.7878G>A(2%) c.3922G>T(3%) c.4829_4830del 
(0.2%) 
c.3847_3848de
l(2%) 
 8 c.8537_8538del(1%) c.2957_2958insG(2%) c.262_263del(2%) c.1813dup(2%) c.5238del(0.2%) c.5682C>G(1%
) 
 9 c.658_659del(1%) c.7024C>T(2%) c.7133C>G(1%) c.9699_9702del(2%) c.9207T>A(0.1%) c.9672dup(1%
) 
 10 c.7934del(1%) c.6531_6534del(2%) c.5164_5165del(1%) c.6275_6276del(@5)  c.3264dup(0.1%) c.658_659del(
1%) 
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Families 7,156 125 538 207 990 2,551  
Unique 
Mutations 
1,242 77 248 91 44 753  
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 Mutation 
Rank 
North America Africa Asia South/Central 
America 
Europe Australia 
BRCA1  1 c.68_69del(26%) c.2641G>T(26%) c.68_69del(47%) c.3331_3334del 
(20%) 
c.5266dup(17%) c.68_69del(10%) 
 2 c.5266dup(13%) c.5266dup(10%) c.5266dup(14%) c.5266dup(16%) c.181T>G(7%) c.5266dup(8%) 
 3 c.181T>G(3%) c.1374del(6%) c.390C>A(2%) c.68_69del(9%) c.68_69del(4%) c.4065_4068del(4%) 
 4 c.4327C>T(2%) c.68_69del(6%) c.5496_5506delinsA 
(2%) 
c.5123C>A(8%) c.4035del(2%) c.3756_3759del(4%) 
 5 c.4065_4068del(1%) c.3228_3229del(6%) c.5503C>T(1%) c.211A>G(5%) c.1687C>T(2%) c.5503C>T(3%) 
 6 c.3756_3759del(1%) c.303T>G(6%) c.2934T>G(1%) c.181T>G(3%) c.4065_4068del(2%) c.4186-?_4357+?dup(3%) 
 7 c.213-11T>G(1%) c.4838_4839insC 
(3%) 
c.3770_3771del(1%) c.548-
?_4183+8?del(3%) 
c.3481_3491del(1%) c.4327C>T(2%) 
 8 c.1687C>T(1%) c.3268C>T(3%) c.2726dup(1%) c.1687C>T(2%) c.2475del(1%) c.5278-?_5592+?del (2%) 
 9 c.4186-
?4357+?dup(1%) 
c.1504_1508del(3%)  c.470_471del(1%) c.135-
?_441+?del(2%) 
c.3756_3759del(1%) c.70_80del(2%) 
 10 c.1175_1214del(1%) c.191G>A(3%) c.922_924delinsT(1%) c.5030_5033del (2%) c.3770_3704del(1%) c.1961del(2%) 
Families 4,669 69 1,100 271 11,748 581  
Unique 
Mutations 
654 30 187 75 1282 173  
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BRCA2 1 c.5946del(23%) c.7934del(47%) c.5946del(34%) c.2808_2811del 
(11%) 
c.6275_6276del(2%) c.5946del(5%) 
 2 c.2808_2811del(3%) c.5946del(4%) c.7480C>T(4%) c.5946del(9%) c.5946del(2%)  c.6275_6276del(2%) 
 3 c.8537_8538del(2%) c.1310_1313del(2%) c.3109C>T(3%) c.2T>G(2%) c.2808_2811del(2%) c.7977-1G>C(1%) 
 4 c.1813dup(2%) c.6944_6947del(1%) c.3744_3747del(2%) c.156_157insAlu 
(2%) 
771_775del(1%) c.5682C>G(1%) 
 5 c.6275_6276del(2%) c.8817_8820del(1%) c.1399A>T(2%) c.6037A>T(2%) c.3847_3848del(1%) c.3847_3848del(1%) 
 6 c.3847_3848del(3%) c.5213_5216del(1%) c.5576_5579del(2%) c.6405_6409del(3) c.1813dup(1%) c.2808_2811del(1%) 
 7 c.658_659del(2%) c.6535_6536insA 
(1%) 
c.2808_2811del(1%) c.5645C>G(1%) c.5682C>G(1%) c.755_758del(1%) 
 8 c.9382C>T(1%) c.774_775del(1%) c.262_263del(1%) c.658_659del(1%) c.1310_1313del(92) c.4478_4481del(1%) 
 9 c.3264dup(1%) c.6393del(1%) c.8537_8538del(1%) c.7180A>T(1%) c.5645C>A(1%) c.8297del(1%) 
 10 c.55073dup(1%) c.5042_5043del(1%) c.7878G>A(1%) c.5851_5854del (1%) c.9026_9030del(1%) c.250C>T(1%) 
Families 3,375 170 976 222 10,175 1,047  
Unique 
Mutations 
660 27 187 58 1,315 179  
 
